about
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerIndividual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial.Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialValidation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer.DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerClinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeHypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialIntermittent androgen suppression for rising PSA level after radiotherapy.The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors.Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-upRandomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialRecovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated RadiotherapySequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate CancerSecond cancer risk and mortality in men treated with radiotherapy for stage I seminomaR-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Clinical development of new drug-radiotherapy combinations.A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial.Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.Defining bowel dose volume constraints for bladder radiotherapy treatment planning.Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results.A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.Implementing electronic data capture (EDC) training for site staff.Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC).Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms.Remote training solutions for complex intervention trials.Dynamic prediction methods in the BC2001 clinical trial.Letter in response to the Wedlake et al. paper 'Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies'.
P50
Q27853235-AFF8F31C-D798-4FF5-9274-421A9F5A4862Q31116483-7AA795F3-08AB-4593-8918-4986CBEA0816Q33676764-C4239193-FF55-4843-A6AE-71757036014CQ34199348-7B876632-FB9D-4D3A-B163-A67B1A996713Q34207562-B2231A7A-41DF-4145-AA8D-55DF8F9E2905Q34240634-A4E43018-BF0C-44A8-BC9A-88F47A2CB9CBQ34551288-7C0583D6-2BF9-4C6A-962F-3D4DB9171F68Q35540043-E40A8C36-EED5-4D1C-8EF9-998D60A630D4Q36156806-1D9178BA-DC6A-4E04-B266-5C83E52891F7Q36265620-150F2689-76C1-4DFE-A3F7-328FBBCD1B67Q36333179-8D14E9C1-FCE3-4E3F-ACF0-270FA964E9A4Q36463238-FA17C806-C7BC-4227-A4F4-4ABBEF166A30Q36561102-AA9AE4E0-5BF4-47A2-B559-64DA5C8F957CQ36887301-603B0B6A-4C26-4A74-B7A3-67A981284DACQ36898448-1029BEAF-1518-4842-BBE3-CA4FCB5B6B84Q37081939-FE6137E5-A00E-46D8-BE5A-318E0F52BC6CQ37121672-9A60D246-77DE-4E19-8F67-4EB78453FC6AQ37128114-B58F23A0-D281-44DC-B478-4AA26805F3A4Q37164413-589BF74E-E9E3-4882-96F0-F9A54BF8C9C2Q37206289-2F39AE27-E17B-42B7-9FA8-D0994690277BQ37283218-9A0418D9-C35C-4A80-95FF-F0976E4D25FAQ37459549-B4A3FC57-637D-41C5-BC0D-C6D76847C7A2Q37735424-C8BF8EA3-0ACD-43B8-8BC9-D1DF649F6A74Q38815964-0F80AC4A-5BB1-4159-96FE-A517230D4AE6Q38849191-A80E74FB-ECA8-468C-A173-D232CF2D3500Q39200585-7868F892-5E55-4387-A278-54E8E7E73BCAQ39571161-988CF39C-A13C-45B4-9244-4C1844647BD5Q40805728-1D99F213-78A5-4A83-A5B8-B80C87409534Q41760505-F5B0B78F-3AAF-4482-884B-EE0791597626Q41872926-31F97EAE-3804-4E5C-873D-E3643879E00DQ42208433-66B38DDD-8F7A-47C3-B054-85834910E11DQ43756593-74F3729A-8440-47E7-ADC2-5D85E11A0E39Q44795543-DF049EC5-C24D-4576-8D65-E706A0AA58E5Q45149588-95538E59-DF7D-4536-B2C3-5E4FF1D1488AQ45978995-2B72CD29-2A36-4688-B27C-381B0844A27EQ45979497-8F36AD1F-B9B4-4AAF-A9FC-FAC393ABF336Q45983087-FBBF2295-4E03-4C67-9E60-624EEBE3871CQ45993341-C2E641BF-A4C3-4EB6-AC0D-FCC8C91CCF16Q45994142-342295B2-F01C-4C54-8BAD-F1765785B66DQ46406570-D94468C9-82FA-4490-BF93-A45CDA9A8830
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emma Hall
@ast
Emma Hall
@en
Emma Hall
@es
Emma Hall
@nl
Emma Hall
@sl
type
label
Emma Hall
@ast
Emma Hall
@en
Emma Hall
@es
Emma Hall
@nl
Emma Hall
@sl
prefLabel
Emma Hall
@ast
Emma Hall
@en
Emma Hall
@es
Emma Hall
@nl
Emma Hall
@sl
P106
P21
P2798
P31
P496
0000-0001-5999-5020